This Article Free upon publication Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Konstam, M. A. Search for Related Content PubMed Articles by Konstam, M. A. Related Collections Congestive Coumarins Platelet function inhibitors

(Circulation. 2009;119:1559-1561.)
© 2009 American Heart Association, Inc.

Editorial

Antithrombotic Therapy in Heart Failure

WATCHful Wondering

Marvin A. Konstam, MD

From The Cardiovascular Center, Tufts Medical Center, and Tufts University School of Medicine, Boston, Mass.

Correspondence to Marvin A. Konstam, MD, Tufts Medical Center, Box 108, 800 Washington St, Boston, MA 02111. E-mail mkonstam@tuftsmedicalcenter.org

Key Words: Editorials • anticoagulants • aspirin • heart failure • platelets • thrombosis

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Clarity regarding the role of antithrombotic treatments in patients with heart failure in the absence of atrial fibrillation remains elusive. In an era of an intensified search for personalized medicine, it is instructive to look back at the earliest evidence for a protective effect of anticoagulation, when little else had any promise to reduce morbidity and mortality in heart failure.^1–3 It is now evident that those benefits were predominantly driven by effects in subsets of patients with atrial fibrillation and valvular disease. Sixty years later, the role of antithrombotic treatments in the remaining population remains uncertain. The Warfarin and Antiplatelet Therapy in Chronic Heart Failure Trial (WATCH), the results of which are published in the present issue,⁴ held the promise of providing clear support for one therapeutic approach above the others in reducing the incidence of adverse cardiovascular events. However, the primary WATCH findings provide no clear winner among warfarin, clopidogrel, and aspirin, with the limited statistical power preventing any clear conclusion. WATCH results do suggest that aspirin treatment increases the likelihood of heart failure hospitalization compared with the other approaches.

Article p 1616

Evidence exists indicating that heart failure is often accompanied by a hypercoagulable state.^5–7 Patients with reduced cardiac output may be predisposed to venous thrombosis and pulmonary embolus. In the sizable percentage of heart failure patients with ischemic heart disease, antiplatelet therapy is expected to decrease the incidence of recurrent coronary ischemic events, as it has been shown to do in the broader ischemic heart disease population.^8–12 . . . [Full Text of this Article]